Davis Polk represented the underwriters, Cooley represented Arlo and its officers and directors, and Wilson Sonsini represented Netgear. In the California state and federal court securities...
Wong v. Arlo Technologies Inc. et al
Acrivon Therapeutics’ $99.4 Million Initial Public Offering
Goodwin Procter advised the underwriters on the deal. Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines...
TD Bank’s $1.3 Billion Acquisition of Cowen
Perella Weinberg Partners LP served as financial advisor, and Simpson Thacher & Bartlett LLP and Torys LLP served as legal advisors to TD, together with Elvinger...
Allbirds’ $302,8 Million Initial Public Offering
Latham & Watkins represented the underwriters in the offering while Cooley advised Allbirds. Allbirds, Inc., a global lifestyle brand that innovates with naturally derived materials to...
GitLab’s $800 Million Initial Public Offering
Fenwick represented GitLab Inc. on the deal, while Latham & Watkins represented the underwriters. GitLab Inc. (Nasdaq: GTLB), provider of The DevOps Platform, announced its initial public...
Brilliant Earth’s $115 Million Initial Public Offering
Latham & Watkins represented Brilliant Earth in the offering while Davis Polk advised the underwriters. Brilliant Earth Group, Inc., an innovative, digital-first jewelry company and global...
Tyra Biosciences’ $172.8 Million Initial Public Offering
Latham & Watkins represented Tyra Biosciences in the offering while Sidley advised the underwriters. Tyra Biosciences, Inc. has announced the pricing of its upsized initial public offering of...
Immuneering’s US$129.4 Million IPO
Sidley Austin advised the underwriters on the deal, while Choate and Latham & Watkins assisted Immuneering Corporation. Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a...
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
SOPHiA GENETICS’ $234 Million Initial Public Offering on Nasdaq
Homburger and Davis Polk advised SOPHiA GENETICS on the deal. Lenz & Staehelin acted as Swiss counsel to the underwriters. SOPHiA GENETICS SA listed its shares...
Ambrx Biopharma’s $126 Million IPO
Goodwin Procter LLP and JunHe advised Goldman Sachs & Co. LLC and the other underwriters on the deal, while Wilson Sonsini Goodrich & Rosati and Maples...
Molecular Partners’ $63.8 Million Initial Public Offering in The US and Listing on NASDAQ Close
Homburger advised Molecular Partners AG in the transaction, while Davis Polk and Advestra advised the joint book-running managers and representatives of the underwriters. Molecular Partners AG,...